Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104155 | 0.83 | — | — | |
| SCHEMBL7310471 | 0.74 | — | — | |
| SCHEMBL4490784 | 0.74 | RAB9A (0.30) | RAB9A | |
| SCHEMBL209742 | 0.73 | — | — | |
| SCHEMBL3547646 | 0.71 | ADRA2B (0.38) | — | |
| SCHEMBL12551238 | 0.70 | RAB9A (0.32) | MEN1KMT2ARAB9A | |
| SCHEMBL15985155 | 0.69 | — | — | |
| SCHEMBL7597 | 0.67 | — | — | |
| SCHEMBL8728 | 0.67 | — | — | |
| SCHEMBL8098 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| US-11173151-B2 | Substituted triazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-16 | — | — | US | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | claimed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | claimed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| US-20200316045-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-10-08 | — | — | US | claimed |
| EP-3700900-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | claimed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | claimed |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | claimed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | claimed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | claimed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | claimed |
| US-5489693-A | ANTICOAGULANTS | DR. KARK THOMAE, GMBH (DE) | 1996-02-06 | — | — | US | claimed |
| EP-0354787-B1 | Oxaspiro[2,5]octane derivative | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-02-15 | — | — | EP | claimed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | claimed |
| EP-0565484-A2 | HIV-protease inhibiting morpholin- and thiomorpholin-4-ylamides | CIBA-GEIGY AG (CH) | 1993-10-13 | — | — | EP | claimed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | MEN1 2739/4885KMT2A 691/4885RAB9A 3231/4885 |
| US-20200216419-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | MEN1 3833/4885KMT2A 1054/4885RAB9A 3698/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | MEN1 2739/4885KMT2A 691/4885RAB9A 3231/4885 |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CHKB, CHKA, CHUK | MEN1 3833/4885KMT2A 1054/4885RAB9A 3698/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MEN1 2963/4885KMT2A 4104/4885RAB9A 2032/4885 |
| US-20200316045-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | GLS, TNNI3, CYP11B2 | MEN1 2977/4885KMT2A 4318/4885RAB9A 2607/4885 |
| US-11173151-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | MEN1 2977/4885KMT2A 4318/4885RAB9A 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.